Nephro Care India made a strong entry on the stock market, with its shares listed at ₹171 each on the NSE SME platform, a 90% increase from its IPO price of ₹90 per share.
Before listing, the grey market premium (GMP) for Nephro Care India shares was ₹175, indicating a 195% premium.
This IPO listing is notable as it follows a new NSE rule, effective from July 4, 2024, capping the price increase for SME IPOs at 90% during the pre-opening session.
Nephro Care India’s IPO opened on June 28 and closed on July 2, with the allotment finalized on July 3 and listing on July 5. The IPO price band was ₹85 to ₹90 per share, raising ₹41.26 crore at the upper end.
The IPO saw high demand, being subscribed 715.78 times overall. The retail category was subscribed 634.12 times, the Qualified Institutional Bidders (QIB) category 245.14 times, and the Non-Institutional Investors (NII) category 1,787.19 times.
Corporate Capitalventures Pvt Ltd managed the IPO, and Bigshare Services Pvt Ltd was the registrar. Nephro Care India, based in Kolkata, provides a range of clinical and lifestyle solutions, focusing on renal insufficiency treatment.
Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.
